전문의약품 제조, 판매업
New Footprint activity — 1 fresh signal just appeared.
The order this company entered each market — oldest to newest
Generic Drug Price Cuts Threaten SMEs
Sign up to see the full signal feed
How (주)보령's international expansion compares to its competitors
(주)보령YouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 (주)보령You | 1 | 0 | +100% | 1 | 62 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
12 technologies detected across the stack.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
7 mentions in the last 90 days.
South Korea's generic drug price cap drops from 53.55% to 45%, threatening small pharmaceutical companies reliant on contract manufacturing, while larger firms receive preferential rates up to 68%.
Samsung Bioepis submitted Korea's first Keytruda biosimilar (SB27) application to MFDS, conducting large-scale Phase 3 trials with 555 patients to maximize data credibility for global partnerships.
Boryung Pharmaceutical achieved record H1 2026 results with revenue of 535 billion won and operating profit of 44 billion won, driven by Taxotere global sales and CDMO business expansion.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about (주)보령's business, markets, and growth signals.
“We reach accounts the week they land in-market — not the quarter after.”
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
© 2026 Pubrio. All rights reserved.
